Simple but strong evidence of the BCG Tokyo strain efficacy against COVID-19
Here is simple but strong evidence of the BCG Tokyo strain efficacy against COVID-19.
One Japanese died of COVID-19 in the U.S at the end of April. It is the first COVID-19 Japanese death in the U.S. Let me calculate and summarize the deaths per 1 million population.
Deaths per 1M at the end of April.
- The U.S.: around 200
- Asian American: 110
- Japanese in the U.S.: around 2
- Japan: 3
2) There should be other biological reasons other than genes. My hypothesis is that BCG vaccination is the key reason.
The BCG Tokyo strain may work as ready-to-use vaccination against COVID-19.
If an adult has BCC vaccinated before, the Mantoux test can work as a second-best solution to resensitize his/her immune memory. This is good because we can keep the necessary BCG vaccine for infants if seniors can use the Mantoux test.
I wonder why only a few researchers work on this hypothesis. I have heard that pharmaceutical companies are not interested in the BCG vaccine because it is a very low margin product. I believe all the governments look into this hypothesis.